HMGCR and renal cell carcinoma: In renal cell carcinoma, treatment with simvastatin, an inhibitor of HMG-CoA reductase, and bufalin suppressed the metastatic activity of RCC cells that was accompanied by inhibition of the Akt/mTOR pathway [41,42].